Genervon Announces Promising Results of its Phase IIb Trial of GM6 in ALS and PD

In July this year, Genervon announced promising results of its Phase IIb clinical trial of GM6 in ALS and Parkinson’s disease (PD) based on biomarker data from the trial. The biotechnology company just released the full results of the study, which provide further support of the disease-modifying effects of this peptide therapy. GM6 is a peptide regulator that modulates inflammatory processes, and has potentially beneficial effects on other pathways implicated in ALS, such as apoptosis and hypoxia. In the small trial of 8 patients, GM6 reduced the decline of the ALS Functional Rating Scale in its revised form (ALSFRS-R) compared to historical controls, as well as slowed decline in Forced Vital Capacity. Genervon has both fast track and orphan drug designation for GM6 in ALS, and has submitted the results to the FDA for further guidance on next steps.

In July this year, Genervon announced promising results of its Phase IIb clinical trial of GM6 in ALS and Parkinson’s disease (PD) based on biomarker data from the trial. The biotechnology company just released the full results of the study, which provide further support of the disease-modifying effects of this peptide therapy. GM6 is a peptide regulator that modulates inflammatory processes, and has potentially beneficial effects on other pathways implicated in ALS, such as apoptosis and hypoxia. In the small trial of 8 patients, GM6 reduced the decline of the ALS Functional Rating Scale in its revised form (ALSFRS-R) compared to historical controls, as well as slowed decline in Forced Vital Capacity. Genervon has both fast track and orphan drug designation for GM6 in ALS, and has submitted the results to the FDA for further guidance on next steps.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail